These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 3024873

  • 1. The effect of ovine corticotrophin releasing factor (oCRF), bromocriptine and TRH on the secretion of ACTH and alpha-MSH in Nelson's syndrome and Cushing's disease.
    Abraham RR, Campbell EA, Gillham B, Thody AJ, Altaher AR, Prysor-Jones A, Wynn V, Jones MT, Jenkins J.
    Clin Endocrinol (Oxf); 1986 Jul; 25(1):75-85. PubMed ID: 3024873
    [Abstract] [Full Text] [Related]

  • 2. Effects of bromocriptine and cyproheptadine on basal and corticotropin-releasing factor (CRF)-induced ACTH release in a patient with Nelson's syndrome.
    Hirata Y, Nakashima H, Uchihashi M, Tomita M, Fujita T, Ikeda M.
    Endocrinol Jpn; 1984 Oct; 31(5):619-26. PubMed ID: 6097444
    [Abstract] [Full Text] [Related]

  • 3. Ovine corticotrophin releasing factor stimulates ACTH release from human corticotrophinoma cells in culture; interaction with hydrocortisone and arginine vasopressin.
    White MC, Adams EF, Loizou M, Mashiter K, Fahlbusch R.
    Clin Endocrinol (Oxf); 1985 Sep; 23(3):295-302. PubMed ID: 3000651
    [Abstract] [Full Text] [Related]

  • 4. Corticotropin-releasing hormone (CRH) stimulation in Nelson's syndrome: response of adrenocorticotropin secretion to pulse injection and continuous infusion of CRH.
    Oldfield EH, Schulte HM, Chrousos GP, Gold PW, Benker G, Peterson RE, Cutler GB, Loriaux DL.
    J Clin Endocrinol Metab; 1986 May; 62(5):1020-6. PubMed ID: 3007552
    [Abstract] [Full Text] [Related]

  • 5. Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.
    Ishibashi M, Yamaji T.
    J Clin Invest; 1981 Oct; 68(4):1018-27. PubMed ID: 6270192
    [Abstract] [Full Text] [Related]

  • 6. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
    van Aken MO, Pereira AM, van den Berg G, Romijn JA, Veldhuis JD, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
    [Abstract] [Full Text] [Related]

  • 7. Plasma ACTH and cortisol responses to TRF, vasopressin or hypoglycemia in cushing's disease and nelson's syndrome.
    Krieger DT, Luria M.
    J Clin Endocrinol Metab; 1977 Feb; 44(2):361-8. PubMed ID: 190254
    [Abstract] [Full Text] [Related]

  • 8. Thyrotropin-releasing hormone stimulation of adrenocorticotropin production by mouse pituitary tumor cells in culture: possible model for anomalous release of adrenocorticotropin by thyrotropin-releasing hormone in some patients with Cushing's disease and Nelson's syndrome.
    Gershengorn MC, Arevalo CO, Geras E, Rebecchi MJ.
    J Clin Invest; 1980 Jun; 65(6):1294-300. PubMed ID: 6251109
    [Abstract] [Full Text] [Related]

  • 9. Effect of ovine corticotrophin releasing factor, bromocriptine, and dopamine on release of ACTH and beta-endorphin in a patient with Cushing's disease.
    Nakashima H, Hirata Y, Uchihashi M, Tomita M, Fujita T.
    Acta Endocrinol (Copenh); 1985 May; 109(1):7-12. PubMed ID: 2988259
    [Abstract] [Full Text] [Related]

  • 10. Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.
    Elias AN, Gwinup G, Valenta LJ.
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):151-4. PubMed ID: 6273025
    [Abstract] [Full Text] [Related]

  • 11. Synergistical effects of ovine corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on the release of pro-opiomelanocortin (POMC) related peptides by pituitary adenoma of a patient with Nelson's syndrome in vitro.
    Chan JS, Gaspar L, Iguchi H, Seidah NG, Ling N, Chrétien M.
    Clin Invest Med; 1984 Aug; 7(4):205-8. PubMed ID: 6335868
    [Abstract] [Full Text] [Related]

  • 12. Unaltered stimulation of pituitary adrenocorticotrophin secretion by corticotrophin-releasing factor following sodium valproate administration in a patient with Nelson's syndrome.
    Gomi M, Iida S, Itoh Y, Moriwaki K, Kanayama S, Namba M, Tarui S.
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):123-7. PubMed ID: 2996808
    [Abstract] [Full Text] [Related]

  • 13. ACTH secretory responsiveness of pituitary adrenotroph cell tumor to adrenocorticotropin-releasing factor in Cushing's disease and Nelson's syndrome.
    Takeda R, Ito T, Kawato M, Nakabayashi H, Miyamori I, Morise T, Koshida H, Ikeda M.
    Exp Clin Endocrinol; 1986 Jun; 87(1):31-7. PubMed ID: 3017732
    [Abstract] [Full Text] [Related]

  • 14. The effects of cortisol, vasopressin (AVP), and corticotropin-releasing factor administration on pulsatile adrenocorticotropin, alpha-melanocyte-stimulating hormone, and AVP secretion in the pituitary venous effluent of the horse.
    Livesey JH, Donald RA, Irvine CH, Redekopp C, Alexander SL.
    Endocrinology; 1988 Aug; 123(2):713-20. PubMed ID: 2840266
    [Abstract] [Full Text] [Related]

  • 15. Dexamethasone inhibits ovine corticotrophin-releasing factor (oCRF), arginine vasopressin (AVP), and oCRF + AVP stimulated release of ACTH during the last third of pregnancy in the sheep fetus.
    Norman LJ, Challis JR.
    Can J Physiol Pharmacol; 1987 Jun; 65(6):1186-92. PubMed ID: 3040203
    [Abstract] [Full Text] [Related]

  • 16. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture.
    Yamaji T, Ishibashi M, Teramoto A, Fukushima T.
    Acta Endocrinol (Copenh); 1985 Apr; 108(4):456-63. PubMed ID: 2859725
    [Abstract] [Full Text] [Related]

  • 17. Hyperprolactinemia in Cushing's disease and Nelson's syndrome.
    Yamaji T, Ishibashi M, Teramoto A, Fukushima T.
    J Clin Endocrinol Metab; 1984 May; 58(5):790-5. PubMed ID: 6323516
    [Abstract] [Full Text] [Related]

  • 18. Clinical studies with synthetic ovine corticotropin-releasing factor.
    Orth DN, DeBold CR, DeCherney GS, Jackson RV, Sheldon WR, Nicholson WE, Uderman H, Alexander AN, Island DP, Rivier J.
    Fed Proc; 1985 Jan; 44(1 Pt 2):197-202. PubMed ID: 2981741
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
    Loli P, Boccardi E, Branca V, Bramerio M, Barberis M, Losa M, Terreni MT, Lodrini S, Pollo B, Vignati F.
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
    [Abstract] [Full Text] [Related]

  • 20. Corticotropin-releasing factor (CRF): stimulation in normal controls and in patients with Cushing's syndrome.
    Müller OA, Hartwimmer J, Hauer A, Kaliebe T, Schopohl J, Stalla GK, von Werder K.
    Psychoneuroendocrinology; 1986 Oct; 11(1):49-60. PubMed ID: 3010360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.